Acme Research LLC — research payments reported

By program year

4 rows

Year	Kind	Amount	Payments
2022	Research	$146	1
2021	Research	$37,907	9
2020	Research	$78,211	19
2019	Research	$11,239	11

Breakdown

Who paid Research payments · program years 2019–2022

Gilead Sciences, Inc. $101,218 16 payments
Pfizer Inc. $22,292 16 payments
Ucb SA $2,343 6 payments
UCB GmBH $1,250 1 payment
GlaxoSmithKline, LLC. $400 1 payment

Studies the money was for Research payments · program years 2019–2022

A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $26,326 1 payment
Phase 3B4 Randomized Safety Endpoint Study of 2 Doses of Tofacitinib in Comparison to A Tumor Necrosis Factor TNF Inhibitor in Subjects With Rheumatoid Arthritis $22,292 16 payments
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $10,164 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $8,226 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $8,041 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $7,238 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $6,018 1 payment
A Long-term Extension Study of Filgotinib Safety and Efficacy in Subjects with Rheumatoid Arthritis $5,946 1 payment
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in Subjects with Active Psoriatic Arthritis Who Have an Inadequate Response or are Intolerant to Biologic DMARD Therapy $5,200 1 payment
A Phase 3, Randomized, Double-blind, Placebo and Adalimumab-controlled Study to Evaluate the Efficacy and Safety of Filgotinib in subjects with Active Psoriatic Arthritis Who Are Naive to Biological DMARD Therapy. $5,200 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.